Kazuyoshi Okada
Research Subjects
Kazuyoshi Okada has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Hiroyuki Michiwaki
Department of Clinical Engineering, Kawashima Hospital, 6-1 Kitasakoiciban-Cho, Tokushima-City 770-0011, Japan
1 shared publication - Hisato Shima
Department of Nephrology and Hypertension, Kamei Hospital
1 shared publication Ikuko Shimizu
Department of Nephrology, Kawashima Hospital
1 shared publicationJun Minakuchi
Department of Nephrology, Kawashima Hospital
1 shared publication- Jun Minakuchi
Department of Nephrology, Kawashima Hospital, Tokushima, Japan, Japan
1 shared publication Manabu Tashiro
Department of Nephrology, Kawashima Hospital
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Japanese Society for Dialysis Therapy in Nihon Toseki Igakkai Zasshi
- Vol. 58 (1) , 31-33
Impact of switching from lanthanum carbonate to tenapanor on CKD‒MBD management
腸管でのNa/H交換輸送体3阻害薬(テナパノル)により厳格な血清リン濃度の管理が期待でき,今回,炭酸ランタンをテナパノルに切り替え,除外基準に該当しない維持血液透析患者27名を後ろ向きに検討した.下痢により,12例(44.4%)が脱落し,除外基準に該当した5例を除いた10例で解析した.リン低下薬錠数は,開始時4.6±1.9錠から12週後2.4±0.9錠と有意に(p<0.01)減少した.血清リン濃度は,開始時5.4±0.9 mg/dLから8週後4.2±0.5 mg/dL,10週後3.9±0.9 mg/dLと有意に(p<0.05,p<0.01)低下した.なお,テナパノルの最終投与量は29.0±13.7 mg/日であった.炭酸ランタンからテナパノルへの切り替えにより,血清リン濃度のコントロールが良好になるとともにポリファーマーシーも改善した.しかし,下痢が開始用量でも高率に発生したため,患者指導により忍容性を高めることが重要である.
- 1 January 2025
- Published by Japanese Society for Dialysis Therapy in Nihon Toseki Igakkai Zasshi
- Vol. 58 (1) , 31-33
Open AccessImpact of switching from lanthanum carbonate to tenapanor on CKD‒MBD management
腸管でのNa/H交換輸送体3阻害薬(テナパノル)により厳格な血清リン濃度の管理が期待でき,今回,炭酸ランタンをテナパノルに切り替え,除外基準に該当しない維持血液透析患者27名を後ろ向きに検討した.下痢により,12例(44.4%)が脱落し,除外基準に該当した5例を除いた10例で解析した.リン低下薬錠数は,開始時4.6±1.9錠から12週後2.4±0.9錠と有意に(p<0.01)減少した.血清リン濃度は,開始時5.4±0.9 mg/dLから8週後4.2±0.5 mg/dL,10週後3.9±0.9 mg/dLと有意に(p<0.05,p<0.01)低下した.なお,テナパノルの最終投与量は29.0±13.7 mg/日であった.炭酸ランタンからテナパノルへの切り替えにより,血清リン濃度のコントロールが良好になるとともにポリファーマーシーも改善した.しかし,下痢が開始用量でも高率に発生したため,患者指導により忍容性を高めることが重要である.
- Open Access
- 24 March 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (7) , 1865
Impact of Albumin Leakage on the Mortality of Patients Receiving Hemodialysis or Online Hemodiafiltration
Background: Online hemodiafiltration (OHDF) has a lower mortality rate than hemodialysis (HD). We aimed to investigate the impact of the albumin leakage on the mortality of patients receiving HD or OHDF. Methods: In this single-center study, consecutive patients receiving renal replacement therapy between January and April 2018 were retrospectively registered. Using (1:1) propensity score matching, 3-year all-cause mortality was compared between patients receiving HD and OHDF, and the impact of albumin leakage on the mortality rate in both groups was investigated. Results: Of the 460 patients, 137 patients receiving HD were matched with an equal number of patients receiving OHDF. OHDF was associated with higher albumin leakage (p < 0.001) and a lower mortality than HD (log-rank test, p < 0.001). Albumin leakage was associated with mortality in patients receiving HD (per 1 g increase, hazard ratio (HR): 0.495, 95% confidence interval (CI): 0.275–0.888) and patients receiving OHDF (per 1 g increase, HR: 0.734, 95% CI: 0.588–0.915). Patients receiving HD, with the highest albumin leakage tertile (>3 g), had a similar mortality rate to patients receiving OHDF, with similar albumin leakage. Conclusions: The negative relationship between albumin leakage and mortality suggests the benefit of removing middle- to -large-molecular-weight substances to improve survival.
- 24 March 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (7) , 1865
Open AccessImpact of Albumin Leakage on the Mortality of Patients Receiving Hemodialysis or Online Hemodiafiltration
Background: Online hemodiafiltration (OHDF) has a lower mortality rate than hemodialysis (HD). We aimed to investigate the impact of the albumin leakage on the mortality of patients receiving HD or OHDF. Methods: In this single-center study, consecutive patients receiving renal replacement therapy between January and April 2018 were retrospectively registered. Using (1:1) propensity score matching, 3-year all-cause mortality was compared between patients receiving HD and OHDF, and the impact of albumin leakage on the mortality rate in both groups was investigated. Results: Of the 460 patients, 137 patients receiving HD were matched with an equal number of patients receiving OHDF. OHDF was associated with higher albumin leakage (p < 0.001) and a lower mortality than HD (log-rank test, p < 0.001). Albumin leakage was associated with mortality in patients receiving HD (per 1 g increase, hazard ratio (HR): 0.495, 95% confidence interval (CI): 0.275–0.888) and patients receiving OHDF (per 1 g increase, HR: 0.734, 95% CI: 0.588–0.915). Patients receiving HD, with the highest albumin leakage tertile (>3 g), had a similar mortality rate to patients receiving OHDF, with similar albumin leakage. Conclusions: The negative relationship between albumin leakage and mortality suggests the benefit of removing middle- to -large-molecular-weight substances to improve survival.